{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:08:13Z","timestamp":1780484893031,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Talaporfin sodium photodynamic therapy (Talaporfin-PDT) shows a high local complete response (L-CR) rate for local failure after chemoradiotherapy in esophageal cancer; however, some patients do not achieve L-CR. We investigated the treatment resistance factors associated with Talaporfin-PDT for local control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 55 consecutive patients with ycT1-2 esophageal cancer who received Talaporfin-PDT. We investigated the L-CR rate, cumulative survival rate according to local effect, and treatment resistance factors associated with Talaporfin-PDT for local control using a multivariate logistic regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The L-CR rate was 65.5% (95% confidence interval [CI]: 52.3\u201376.6). During the median follow-up of 17.8\u00a0months (range, 1.7\u201369.3), the 1-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were significantly higher in patients who achieved L-CR than in those who did not: 97.0% vs. 75.6% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008), 64.6% vs. 0% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and 97.0% vs. 85.7% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005), respectively. In the multivariate logistic regression model, esophageal stenosis before Talaporfin-PDT was an independent predictor of local failure after Talaporfin-PDT (odds ratio: 5.626, 95% CI: 1.051\u201330.124,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.044). The 1-year OS and DSS rates were significantly lower in patients with stenosis before Talaporfin-PDT than in those without: 75.0% vs. 92.4% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.015) and 85.7% vs. 94.6% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.015), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Esophageal stenosis before Talaporfin-PDT was associated with resistance to local control and poor survival. The indications for the use of Talaporfin-PDT in patients with stenosis should be considered carefully.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10388-025-01177-w","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:57:50Z","timestamp":1768586270000},"page":"391-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Masashi","family":"Tamaoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikatoshi","family":"Katada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshiro","family":"Hirohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Amanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Horimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Yamahigashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Inoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Sakanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nikaido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Obama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-8203","authenticated-orcid":false,"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"1177_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941\u201353.","journal-title":"Int J Cancer"},{"key":"1177_CR2","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1053\/j.gastro.2015.08.054","volume":"149","author":"S Ohashi","year":"2015","unstructured":"Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 2015;149:1700\u201315.","journal-title":"Gastroenterology"},{"key":"1177_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0360-3016(03)00585-6","volume":"57","author":"S Hironaka","year":"2003","unstructured":"Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T2\u20133Nany M0 squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1177_CR4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593\u20138.","journal-title":"N Engl J Med"},{"key":"1177_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jtcvs.2008.05.016","volume":"137","author":"Y Tachimori","year":"2009","unstructured":"Tachimori Y, Kanamori N, Uemura N, et al. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137:49\u201354.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1177_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1067\/mtc.2002.119070","volume":"123","author":"SG Swisher","year":"2002","unstructured":"Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175\u201383.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1177_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.amjsurg.2004.06.003","volume":"188","author":"T Nakamura","year":"2004","unstructured":"Nakamura T, Hayashi K, Ota M, et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. 2004;188:261\u20136.","journal-title":"Am J Surg"},{"key":"1177_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1055\/s-2008-1077480","volume":"40","author":"T Yano","year":"2008","unstructured":"Yano T, Muto M, Hattori S, et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008;40:717\u201321.","journal-title":"Endoscopy"},{"key":"1177_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dote.12037","volume":"27","author":"M Makazu","year":"2014","unstructured":"Makazu M, Kato K, Takisawa H, et al. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer. Dis Esophagus. 2014;27:42\u20139.","journal-title":"Dis Esophagus"},{"key":"1177_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1067\/mge.2003.306","volume":"58","author":"S Hattori","year":"2003","unstructured":"Hattori S, Muto M, Ohtsu A, et al. EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc. 2003;58:65\u201370.","journal-title":"Gastrointest Endosc"},{"issue":"suppl 5","key":"1177_CR11","doi-asserted-by":"publisher","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","volume":"27","author":"F Lordick","year":"2016","unstructured":"Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50-57.","journal-title":"Ann Oncol"},{"key":"1177_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10388-018-0642-8","volume":"16","author":"Y Kitagawa","year":"2019","unstructured":"Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 2. Esophagus. 2019;16:25\u201343.","journal-title":"Esophagus"},{"key":"1177_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506\u201317.","journal-title":"Lancet Oncol"},{"key":"1177_CR14","doi-asserted-by":"publisher","first-page":"22135","DOI":"10.18632\/oncotarget.14029","volume":"8","author":"T Yano","year":"2017","unstructured":"Yano T, Kasai H, Horimatsu T, et al. A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget. 2017;8:22135\u201344.","journal-title":"Oncotarget"},{"key":"1177_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00464-019-06846-3","volume":"34","author":"T Minamide","year":"2020","unstructured":"Minamide T, Yoda Y, Hori K, et al. Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Surg Endosc. 2020;34:899\u2013906.","journal-title":"Surg Endosc"},{"key":"1177_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/den.13730","volume":"33","author":"Y Amanuma","year":"2021","unstructured":"Amanuma Y, Horimatsu T, Ohashi S, et al. Association of local complete response with prognosis after salvage photodynamic therapy for esophageal squamous cell carcinoma. Dig Endosc. 2021;33:355\u201363.","journal-title":"Dig Endosc"},{"key":"1177_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10388-020-00734-9","volume":"17","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Kadota T, Yoda Y, et al. Review of early endoscopic findings in patients with local recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Esophagus. 2020;17:433\u20139.","journal-title":"Esophagus"},{"key":"1177_CR18","unstructured":"James D. Brierley. TNM Classification of Malignant Tumours, 8th edition. 1 November 2016."}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-025-01177-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:18:27Z","timestamp":1774984707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-025-01177-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1007\/s10388-025-01177-w","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflict of interest is as follows: Masashi Tamaoki and Chikatoshi Katada belong to industry-academia collaboration courses of Meiji Seika Pharma Co., Ltd. Akira Yokoyama, Kenshiro Hirohashi, Yosuke Mitani, Yusuke Amanuma, Takahiro Horimatsu, Hirokazu Higuchi, Natsuko Yamahigashi, Motoo Nomura, Hiroyuki Inoo, Katsuyuki Sakanaka, Mitsuhiro Nikaido, Takayuki Shimizu, Yo Kishimoto, Shigeru Tsunoda, Kazutaka Obama, and Shinya Ohashi declare that they have no conflict of interest. Muto M received a research grant from Meiji Seika Pharma Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was approved by the Kyoto University Hospital ethics committee. An opt-out method was used in this study. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}